Initial Experience With the AngioVac Venous Drainage Cannula
1 other identifier
observational
51
1 country
5
Brief Summary
This is a retrospective, record-based study of approximately 100 patients across up to 12 centers within the United States. All patients who have been treated with the AngioVac Venous Drainage Cannula and the Extracorporeal Circuit will be considered for study participation. Eligible subject must meet all of the inclusion criteria and none of the exclusion criteria to be considered enrolled in the study. The purpose of the study is to describe initial experience with the AngioVac Venous Drainage Cannula and the Extracorporeal Circuit.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Feb 2016
5 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2016
CompletedFirst Submitted
Initial submission to the registry
April 25, 2016
CompletedFirst Posted
Study publicly available on registry
May 17, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2017
CompletedDecember 8, 2017
December 1, 2017
7 months
April 25, 2016
December 6, 2017
Conditions
Outcome Measures
Primary Outcomes (1)
Detailing early clinical experience with the AngioVac Venous Drainage Cannula
Experience and success is determined immediately after the procedure is completed. No subject follow up data is collected and retrospective data will be reviewed.
Interventions
Eligibility Criteria
patients treated at each study site between February 1, 2013 and February 28, 2015 will be included.
You may qualify if:
- Consecutive patients treated at each study site between February 1, 2013 and February 28, 2015 will be included.
You may not qualify if:
- Patients treated with the AngioVac venous drainage system outside of those dates.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (5)
Providence St. Joseph
Burbank, California, 91505, United States
UCLA
Los Angeles, California, 90024, United States
Sanford Research
Fargo, North Dakota, 58122, United States
MUSC
Charleston, South Carolina, 29425, United States
Swedish Health Services
Seattle, Washington, 98122, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 25, 2016
First Posted
May 17, 2016
Study Start
February 1, 2016
Primary Completion
September 1, 2016
Study Completion
May 1, 2017
Last Updated
December 8, 2017
Record last verified: 2017-12